37 Blood Proteins in Centenarians Reveal the Secrets of Exceptional Longevity
New genetic and proteomic findings from centenarian studies uncover biological markers that distinguish the longest-lived humans from the rest of us.
Summary
A wave of April 2026 longevity research is reshaping how scientists understand extreme aging. The Swiss 100 study identified 37 blood proteins in centenarians tied to slower biological aging, including lower inflammation, reduced oxidative stress, and better tissue maintenance. Separately, an $80 million grant is advancing the Long Life Family Study, which has already uncovered a novel Alzheimer's-protective gene variant and better cardiovascular profiles in long-lived families. A 'longevity gene' from supercentenarians improved heart function in premature aging mouse models. Meanwhile, researchers note that 75% of longevity is non-genetic, pointing to lifestyle as the dominant driver. These findings collectively suggest that exceptional longevity reflects a systems-level resilience — not a single gene or habit — involving mitochondria, metabolism, microbiome, and inflammation control.
Detailed Summary
Why does this matter? Centenarians are nature's experiment in successful aging. Understanding what makes them biologically distinct could unlock interventions that extend healthy lifespan for everyone — not just the genetically fortunate. A cluster of studies published in April 2026 offers some of the clearest answers yet.
The Swiss 100 study analyzed blood proteins in centenarians and identified 37 markers associated with slower aging. These included lower levels of interleukin-1 alpha (a key inflammatory signal), reduced oxidative stress indicators, fewer signs of metabolic dysfunction, and better-preserved extracellular matrix regulation — the structural scaffolding that keeps tissues youthful. Centenarians also showed less age-related fat metabolism disruption and elevated levels of proteins potentially linked to cancer defense.
On the genetic front, Washington University School of Medicine received an $80 million grant to expand the Long Life Family Study. Early findings include a novel Alzheimer's-protective gene variant and superior cardiovascular health in long-lived family lineages. A separate discovery identified LAV-BPIFB4, a 'longevity gene' found in supercentenarians, which improved cardiac function in mouse models of progeria — a disease of accelerated aging.
Not all news was optimistic. Research on life expectancy trends found that gains in high-income countries have stalled, with no birth cohorts after 1939 projected to reach 100 on average. Early-life survival improvements that once drove longevity gains have largely plateaued.
The 2nd World Congress on Targeting Longevity framed aging as a loss of biological coordination across mitochondria, microbiota, and metabolism. Critically, researchers emphasize that genetics accounts for only about 25% of longevity variance — meaning lifestyle interventions remain the most powerful lever available to most people. These findings collectively point toward a systems-biology model of aging where resilience, not any single factor, defines exceptional lifespan.
Key Findings
- 37 blood proteins in centenarians linked to lower inflammation, oxidative stress, and better tissue maintenance.
- Novel Alzheimer's-protective gene variant identified in long-lived families via the Long Life Family Study.
- LAV-BPIFB4 longevity gene from supercentenarians improved heart function in premature aging mouse models.
- Life expectancy gains have stalled in high-income countries; no post-1939 cohorts projected to average 100.
- 75% of longevity is non-genetic, reinforcing lifestyle as the dominant driver of exceptional lifespan.
Methodology
This press release synthesizes findings from multiple studies, including the Swiss 100 centenarian proteomics study, the Long Life Family Study genetic analysis, mouse model experiments with LAV-BPIFB4, and life expectancy trend analyses. Individual study designs, sample sizes, and statistical methods are not detailed in the abstract. The summary draws on conference proceedings from the 2nd World Congress on Targeting Longevity (Berlin, April 2026).
Study Limitations
This summary is based on the abstract only; full study methodologies, sample sizes, and statistical details are unavailable. The press release aggregates multiple distinct studies, making it difficult to assess the strength of evidence for any single finding. Mouse model results for LAV-BPIFB4 may not translate directly to human cardiac aging therapies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.